L. Mary Smith

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

M. Fevzi Özkaynak, Andrew L. Gilman, Wendy B. London et al. · Frontiers in Immunology · 2018 · 91 citations · Full text

Pharmacy, Oncology, Pharmacology +17

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

Christopher L. Moertel, Angela C. Hirbe, Hans Shuhaiber et al. · Journal of Clinical Oncology · 2024 · 87 citations · Full text

Medicine, Neurology, Neuroscience +7

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

Ami V. Desai, Elizabeth Fox, L. Mary Smith et al. · Cancer Chemotherapy and Pharmacology · 2014 · 38 citations

Pharmacy, Oncology, Pharmacokinetics +9

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

Araz Marachelian, Ami V. Desai, Frank M. Balis et al. · Cancer Chemotherapy and Pharmacology · 2016 · 22 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Neuroblastoma in an adult: case presentation and literature review.

L. Mary Smith, Steve Minter, Paul H. O’Brien et al. · PubMed · 2013 · 17 citations

Medicine, Oncology, Pediatrics +13